Separate and combined impact of acute naltrexone and alprazolam on subjective and physiological effects of oral d-amphetamine in stimulant users

Psychopharmacology

Volumn 231, Issue 14, 2014, Pages 2741-2750

  Marks, Katherine R ^a   Lile, Joshua A ^b   Stoops, William W ^a,b   Rush, Craig R ^a,b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Alprazolam; d Amphetamine; Naltrexone; Subjective effects

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ALPRAZOLAM; AMPHETAMINE; NALTREXONE; OPIATE ANTAGONIST; PLACEBO; BENZODIAZEPINE RECEPTOR AFFECTING AGENT; CENTRAL STIMULANT AGENT; DEXAMPHETAMINE; NARCOTIC ANTAGONIST;

ADULT; ARTICLE; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DRUG ABUSE; DRUG BLOOD LEVEL; DRUG DEPENDENCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; FEMALE; HUMAN; MALE; PILOT STUDY; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; SUBSTANCE ABUSE; TASK PERFORMANCE; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE; COMPARATIVE STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; DRUG EFFECTS; MIDDLE AGED; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; ALPRAZOLAM; CENTRAL NERVOUS SYSTEM STIMULANTS; DEXTROAMPHETAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GABA MODULATORS; HUMANS; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; PILOT PROJECTS; PSYCHOMOTOR PERFORMANCE;

EID: 84903595821     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-014-3449-x     Document Type: Article

References (71)

1. Abernethy DR, Greenblatt DJ, Divoll M et al (1983) Pharmacokinetics of alprazolam. J Clin Psychiatry 44:45-47
2. Ambrose LM, Unterwald EM, Van Bockstaele EJ (2004) Ultrastructural evidence for co-localization of dopamine D2 and mu-opioid receptors in the rat dorsolateral striatum. Anat Rec 279:583-591
3. Angrist B, Corwin J, Bartlik B, Cooper T (1987) Early pharmacokinetics and clinical effects of oral d-amphetamine in normal subjects. Biol Psychiatry 22:1357-1368
4. Anton RF, O'Malley SS, Ciraulo DA et al (2006) Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study. A randomized controlled trial. JAMA 295:2003-2017
5. Barrett AC, Negus SS, Mello NK, Caine SB (2005) Effect of GABA agonists and GABA-A receptor modulators on cocaine- and food-maintained responding and cocaine discrimination in rats. J Pharmacol Exp Ther 315:858-871
6. Chouinard G (2004) Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. J Clin Psychiatry 65(Suppl 5):7-12
7. Churchill L, Dilts RP, Kalivas PW (1992) Autoradiographic localization of gamma-aminobutyric acid receptors within the ventral tegmental area. Neurochem Res 17:101-106
8. Comer SD, Mogali S, Saccone PA et al (2013) Effects of acute oral naltrexone on the subjective physiological effects of oral d-amphetamine and smoked cocaine in cocaine abusers. Neuropsychopharmacology 38:2427-2438
9. Dettmar PW, Cowan A, Walter DS (1978) Naloxone antagonizes behavioural effects of d-amphetamine in mice and rats. Neuropharmacology 17:1041-1044
10. Dewey SL, Chaurasia CS, Chen CE et al (1997) GABAergic attenuation of cocaine-induced dopamine release and locomotor activity. Synapse 25:393-398
11. Ehrman RN, Robbins SJ, Bromwell MA, Lankford ME, Monterosso JR, O'Brien CP (2002) Comparing attentional bias to smoking cues in current smokers, former smokers, and non-smokers using a dot-probe task. Drug Alcohol Depend 67:185-191
12. Elkashef A, Vocci F, Hanson G, White J, Wickes W, Tiihonen J (2008) Pharmacotherapy of methamphetamine addiction: an update. Subst Abuse 29:31-49
13. Ermer JC, Dennis K, Haffey MB et al (2011) Intranasal versus oral administration of lisdexamfetamine dimesylate: a randomized, open-label, two-period, crossover, single-dose, single-centre pharmacokinetic study in healthy adult men. Clin Drug Investig 31:357-370
14. Fillmore MT, Rush CR, Marczinski CA (2003) Effects of d-amphetamine on behavioral control in stimulant abusers: the role of prepotent response tendencies. Drug Alcohol Depend 71:143-152
15. Garbutt JC (2010) Efficacy and tolerability of naltrexone in the management of alcohol dependence. Curr Pharm Des 16:2091-2097
16. Gatch MB, Selvig M, Forster MJ (2005) GABAergic modulation of the discriminative-stimulus effects of methamphetamine. Behav Pharmacol 16:261-266
17. Goeders NE, Guerin GF (2008) Effects of the combination of metyrapone and oxazepam on cocaine and food self-administration in rats. Pharmacol Biochem Behav 91:181-189
18. Goeders NE, McNulty MA, Mirkis S, McAllister KH (1989) Chlordiazepoxide alters intravenous cocaine self-administration in rats. Pharmacol Biochem Behav 33:859-866
19. Goeders NE, McNulty MA, Guerin GF (1993) Effects of alprazolam on intravenous cocaine self-administration in rats. Pharmacol Biochem Behav 44:471-474
20. Greenblatt DJ, Wright CE (1993) Clinical pharmacokinetics of alprazolam. Clin Pharmacokinet 24:453-471
21. Greenblatt DJ, Divoll M, Abernethy DR et al (1983) Clinical pharmacokinetics of the newer benzodiazepines. Clin Pharmacokinet 8:233-252
22. Griffiths RR, Lamb RJ, Ator NA, Roache JD, Brady JV (1985) Relative abuse liability of triazolam: experimental assessment in animals and humans. Neurosci Biobehav Rev 9:133-151
23. Griffiths RR, Bigelow GE, Ator NA (2003) Principles of initial experimental drug abuse liability assessment in humans. Drug Alcohol Depend 70:S41-S54
24. Haggkvist J, Lindholm S, Franck J (2009) The effect of naltrexone on amphetamine-induced conditioned place preference and locomotor behaviour in the rat. Addict Biol 14:260-269
25. Hollister LE, Johnson K, Boukhabza D, Gillespie HK (1981) Aversive effects of naltrexone in subjects not dependent on opiates. Drug Alcohol Depend 8:37-41
26. Holtzman SG (1974) Behavioral effects of separate and combined administration of naloxone and d-amphetamine. J Pharmacol Exp Ther 189:51-60
27. Hooks MS, Jones DN, Justice JB Jr, Holtzman SG (1992) Naloxone reduces amphetamine-induced stimulation of locomotor activity and in vivo dopamine release in the striatum and nucleus accumbens. Pharmacol Biochem Behav 42:765-770
28. Janssen SA, Arntz A (1999) No interactive effects of naltrexone and benzodiazepines on pain during phobic fear. Behav Res Ther 37:77-86
29. Jayaram-Lindström N, Wennberg P, Hurd YL, Franck J (2004) Effects of naltrexone on the subjective response to amphetamine in healthy volunteers. J Clin Psychopharmacol 24:665-669
30. Jayaram-Lindström N, Hammarberg A, Beck O, Franck J (2008a) Naltrexone for the treatment of amphetamine dependence: a randomized, placebo-controlled trial. Am J Psychiatry 165:1442-1448
31. Jayaram-Lindström N, Konstenius M, Eksborg S, Beck O, Hammarberg A, Franck J (2008b) Naltrexone attenuates the subjective effects of amphetamine in patients with amphetamine dependence. Neuropsychopharmacology 33:1856-1863
32. Jimenez-Gomez C, Winger G, Dean RL, Deaver DR, Woods JH (2010) Naltrexone decreases D-amphetamine and ethanol self-administration in rhesus monkeys. Behav Pharmacol 22:87-90
33. Johanson CE, Lundahl LH, Lockhard N, Schubiner H (2006) Intravenous cocaine discrimination in humans. Exp Clin Psychopharmacol 14:99-108
34. Kablinger AS, Lindner MA, Casso S et al (2012) Effects of the combination of metyrapone and oxazepam on cocaine craving and cocaine taking: a double-blind, randomized, placebo-controlled pilot study. J Psychopharmacol 26:973-981
35. Karila L, Weinstein A, Aubin HJ, Benyamina A, Reynaud M, Batki SL (2010) Pharmacological approaches to methamphetamine dependence: a focused review. Br J Clin Pharmacol 69:578-592
36. Lamb RJ, Henningfield JE (1994) Human d-amphetamine drug discrimination: methamphetamine and hydromorphone. J Exp Anal Behav 61:169-180
37. Lee MC, Wagner HN Jr, Tanada S, Frost JJ, Bice AN, Dannals RF (1988) Duration of occupancy of opiate receptors by naltrexone. J Nucl Med 29:1207-1211
38. Lejuez CW, Read JP, Kahler CW et al (2002) Evaluation of a behavioral measure of risk taking: the Balloon Analogue Risk Taking (BART). J Exp Psychol Appl 8:75-84
39. Lile JA, Stoops WW, Glaser PEA, Hays LR, Rush CR (2011a) Subjective and physiological effects of acute intranasal methamphetamine during extended-release alprazolam maintenance. Drug Alcohol Depend 119:187-193
40. Lile JA, Stoops WW, Glaser PEA, Hays LR, Rush CR (2011b) Discriminative stimulus, subject-rated and cardiovascular effects of cocaine alone and in combination with aripiprazole in humans. J Psychopharmacol 25:1469-1479
41. Liu S, Lane SD, Schmitz JM, Waters AJ, Cunningham KA, Moeller FG (2011) Relationship between attentional bias to cocaine-related stimuli and impulsivity in cocaine-dependent subjects. Am J Drug Alcohol Abuse 37:117-122
42. Makris AP, Rush CR, Frederich RC, Taylor AC, Kelly TH (2007) Behavioral and subjective effects of d-amphetamine and modafinil in humans. Exp Clin Psychopharmacol 15:123-133
43. McLeod DR, Griffiths RR, Bigelow GE, Yingling JE (1982) An automated version of the digit symbol substitution test (DSST). Behav Res Methods Instrum 14:463-466
44. Meltzer HY (2013) Update on typical and atypical antipsychotic drugs. Annu Rev Med 64:393-406
45. Meyer MC, Straughn AB, Lo MW, Schary WL, Whitney CC (1984) Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration. J Clin Psychiatry 45:15-19
46. Mumford GK, Evans SM, Fleishaker JC, Griffiths RR (1995a) Alprazolam absorption kinetics affects abuse liability. Clin Pharmacol Ther 57:356-365
47. Mumford GK, Rush CR, Griffiths RR (1995b) Abecarnil and alprazolam in humans: behavioral, subjective and reinforcing effects. J Pharmacol Exp Ther 272:570-580
48. Negus SS, Mello NK, Fivel PA (2000) Effects of GABA agonists and the GABA-A receptor modulators on cocaine discrimination in rhesus monkeys. Psychopharmacology 152:398-407
49. Oliveto AH, Bickel WK, Hughes JR, Shea PJ, Higgins ST, Fenwick JW (1992) Caffeine drug discrimination in humans: acquisition, specificity, and correlation with self-reports. J Pharmacol Exp Ther 261:885-894
50. Oliveto AH, McCance-Katz E, Singha A, Hameedi F, Kosten TR (1998) Effects of d-amphetamine and caffeine in humans under a cocaine discrimination procedure. Behav Pharmacol 9:207-217
51. Pfohl DN, Allen JI, Atkinson RL et al (1986) Naltrexone hydrochloride (Trexan): a review of serum transaminase elevations at high dosage. NIDA Res Monogr 67:66-72
52. Pierce RC, Kumaresan V (2006) The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse? Neurosci Biobehav Rev 30:215-238
53. Pollard H, Llorens C, Bonnet JJ, Costentin J, Schwartz JC (1977) Opiate receptors on mesolimbic dopaminergic neurons. Neurosci Lett 7:295-299
54. Rothman RB, Baumann MH, Dersch CM et al (2001) Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39:32-41
55. Rush CR, Higgins ST, Bickel WK, Hughes JR (1993) Abuse liability of alprazolam relative to other commonly used benzodiazepines: a review. Neurosci Biobehav Rev 17:277-285
56. Rush CR, Stoops WW, Hays LR, Glaser PE, Hays LS (2003) Risperidone attenuates the discriminative-stimulus effects of d-amphetamine in humans. J Pharmacol Exp Ther 306:195-204
57. Rush CR, Stoops WW, Wagner FP, Hays LR, Glaser PEA (2004) Alprazolam attenuates the behavioral effects of d-amphetamine in humans. J Clin Psychopharmacol 24:410-420
58. Rush CR, Vansickel AR, Lile JA, Stoops WW (2009) Evidence-based treatment of amphetamine dependence: behavioral and pharmacological approaches. In: Cohen L, Collins FL, Young AM, McChargue DE, Leffingwell TR, Cook KL (eds) Pharmacology and treatment of substance abuse: evidence- and outcome-based perspectives. Routledge, Taylor and Francis Group, New York, pp 335-358
59. Schad CA, Justice JB Jr, Holtzman SG (1995) Naloxone reduces the neurochemical and behavioral effects of amphetamine but not those of cocaine. Eur J Pharmacol 275:9-16
60. Sevak RJ, Stoops WW, Hays LR, Rush CR (2009) Discriminative stimulus and subject-rated effects of methamphetamine, d-amphetamine, methylphenidate, and triazolam in methamphetamine-trained humans. J Pharmacol Exp Ther 328:1007-1018
61. Sevak RJ, Stoops WW, Glaser PEAG, Hays LR, Rush CR (2010) Reinforcing effects of d-amphetamine: influence of novel ratios on a progressive-ratio schedule. Behav Pharmacol 21:745-753
62. Smith RB, Kroboth PD (1987) Influence of dosing regimen on alprazolam and metabolite serum concentrations and tolerance to sedative and psychomotor effects. Psychopharmacology 93:105-112
63. Stoops WW, Glaser PEA, Fillmore MT, Rush CR (2004) Reinforcing, subject-rated, performance and physiological effects of methylphenidate and d-amphetamine in stimulant abusing humans. J Psychopharmacol 18:534-543
64. Stoops WW, Vansickel AR, Lile JA, Rush CR (2007) Acute d-amphetamine pretreatment does not alter stimulant self-administration in humans. Pharmacol Biochem Behav 87:20-29
65. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality (2012) Treatment Episode Data Set (TEDS): 2000-2010. State Admissions to Substance Abuse Treatment Services. DASIS Series S-63, HHS Publication No. (SMA) 12-4729. Rockville, MD
66. Tiihonen J, Krupitsky E, Verbitskaya E et al (2012) Naltrexone implant for the treatment of polydrug dependence: a randomized controlled trial. Am J Psychiatry 169:531-536
67. Trujillo KA, Belluzzi JD, Stein L (1991) Naloxone blockade of amphetamine place preference conditioning. Psychopharmacology 104:265-274
68. United Nations Office of Drugs and Crime (2012) World Drug Report 2012. United Nations Vienna, pp 7-9
69. Volpicelli JR, Alterman AI, Hayashida M et al (1992) Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 49:876-880
70. Walsh SL, Sullivan JT, Preston KL, Garner JE, Bigelow GE (1996) Effects of naltrexone on response to intravenous cocaine, hydromorphone and their combination in humans. J Pharmacol Exp Ther 279:524-538
71. Weerts EM, Froestl W, Griffiths RR (2005) Effects of GABAergic modulators on food and cocaine self-administration in baboons. Drug Alcohol Depend 80:369-376